| Name | Title | Contact Details |
|---|
Deaconess HomeCare is a Hattiesburg, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Johnson & Johnson Health Care Systems Inc. (JJHCS) provides contracting, supply chain, business services, and strategic solutions to customers and commercial intermediaries of U.S.-based Johnson & Johnson (J&J) companies, including hospital systems, health plans, distributors, wholesalers, purchasing organizations, government payer programs, and government healthcare institutions in the U.S. JJHCS also engages with customers to provide streamlined supply chain services for our products that seamlessly integrate with customer operations, address shared evolving market challenges to value-based care, and develop innovative solutions that improve patient care and access.
Genairex is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Atrium Health, formerly Carolinas HealthCare System, is a not for profit hospital network which operates hospitals, freestanding emergency departments, urgent care centers, and medical practices in the American states of North Carolina, South Carolina ...
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.